JP2022546410A5 - - Google Patents
Info
- Publication number
- JP2022546410A5 JP2022546410A5 JP2022513159A JP2022513159A JP2022546410A5 JP 2022546410 A5 JP2022546410 A5 JP 2022546410A5 JP 2022513159 A JP2022513159 A JP 2022513159A JP 2022513159 A JP2022513159 A JP 2022513159A JP 2022546410 A5 JP2022546410 A5 JP 2022546410A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- alkyl
- hydroxyacetamide
- difluorophenyl
- methylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893512P | 2019-08-29 | 2019-08-29 | |
| US62/893,512 | 2019-08-29 | ||
| PCT/US2020/048619 WO2021041973A1 (en) | 2019-08-29 | 2020-08-28 | Perk inhibiting compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546410A JP2022546410A (ja) | 2022-11-04 |
| JP2022546410A5 true JP2022546410A5 (cg-RX-API-DMAC7.html) | 2023-08-28 |
Family
ID=72521702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513159A Pending JP2022546410A (ja) | 2019-08-29 | 2020-08-28 | Perk阻害化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12473296B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4021893A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022546410A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220068224A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114585606A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020340427A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003768A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152512A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290881A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002443A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550497A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021041973A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
| CN115461323A (zh) | 2020-03-11 | 2022-12-09 | 艾德凡斯化学公司 | 用于农用产品的表面活性剂 |
| US20250000859A1 (en) | 2021-08-25 | 2025-01-02 | Alesta Therapeutics BV | Use of gcn2 inhibitors in treating cancer |
| JP2026513203A (ja) * | 2023-03-30 | 2026-04-23 | ハイバーセル,インコーポレイテッド | (r)-2-アミノ-5-(4-(2-(3,5-ジフルオロフェニル)-2-ヒドロキシアセトアミド)-2-メチルフェニル)-n-イソプロピルニコチンアミドの結晶形態及びその使用方法 |
| GB202407386D0 (en) | 2024-05-24 | 2024-07-10 | Apollo Ap45 Ltd | 1H-pyrazolo(4,3-D)pyrimidine derivatives |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
| BR9808281A (pt) | 1997-03-19 | 2000-05-16 | Basf Ag | Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| DE602004015429D1 (de) * | 2003-03-11 | 2008-09-11 | Pfizer Prod Inc | Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf) |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| WO2005020921A2 (en) * | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| CN101253152A (zh) | 2005-09-02 | 2008-08-27 | 安斯泰来制药株式会社 | 作为rock抑制剂的酰胺衍生物 |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| WO2010080992A1 (en) | 2009-01-09 | 2010-07-15 | The Trustees Of The University Of Pennsylvania | Regulators of the interferon-alpha receptor 1 (ifnar1) chain of the interferon receptor |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| WO2014170706A1 (en) * | 2013-04-15 | 2014-10-23 | Università Degli Studi Di Bari | Galloyl benzamide-based compounds as jnk modulators |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| EP3067356B1 (en) | 2013-11-08 | 2018-07-04 | ONO Pharmaceutical Co., Ltd. | Pyrrolo pyrimidine derivative |
| JP2017507967A (ja) | 2014-03-11 | 2017-03-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Perk阻害剤として作用する化合物 |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| EP3218378B1 (en) | 2014-11-14 | 2020-01-08 | Nerviano Medical Sciences S.r.l. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| EP3481831B1 (en) | 2016-07-07 | 2023-09-06 | Daewoong Pharmaceutical Co., Ltd. | 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same |
| CN109789135A (zh) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为perk抑制剂的异喹啉衍生物 |
| CN106748989B (zh) * | 2016-11-14 | 2020-03-17 | 西安交通大学 | 一种具有抗肿瘤活性的二芳基脲类化合物及其制备方法和应用 |
| WO2018138358A1 (en) | 2017-01-30 | 2018-08-02 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
| SI3612519T1 (sl) | 2017-04-18 | 2022-04-29 | Eli Lilly And Company | Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine |
| KR102740831B1 (ko) | 2017-11-14 | 2024-12-11 | 칠드런'즈 메디컬 센터 코포레이션 | 신규 이미다조피리미딘 화합물 및 그의 용도 |
| EP3717459B1 (en) * | 2017-11-30 | 2026-01-21 | Step Pharma S.A.S. | Compounds |
| EP3492454A1 (en) * | 2017-11-30 | 2019-06-05 | Step Pharma S.A.S. | Compounds |
| KR102897382B1 (ko) * | 2018-03-26 | 2025-12-08 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 미세 잔존 암을 치료하는 방법 |
| AU2019297428C1 (en) | 2018-07-06 | 2023-03-23 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US20220040183A1 (en) | 2018-10-01 | 2022-02-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of inhibitors of stress granule formation for targeting the regulation of immune responses |
| WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
| KR20220066290A (ko) | 2019-08-29 | 2022-05-24 | 히버셀, 인크. | Perk 억제 피롤로피리미딘 화합물 |
| WO2021041976A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting indolinyl compounds |
| WO2021041970A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting imidazolopyrazine compounds |
-
2020
- 2020-08-28 WO PCT/US2020/048619 patent/WO2021041973A1/en not_active Ceased
- 2020-08-28 CA CA3152512A patent/CA3152512A1/en active Pending
- 2020-08-28 EP EP20772466.7A patent/EP4021893A1/en not_active Withdrawn
- 2020-08-28 PH PH1/2022/550497A patent/PH12022550497A1/en unknown
- 2020-08-28 JP JP2022513159A patent/JP2022546410A/ja active Pending
- 2020-08-28 US US17/639,169 patent/US12473296B2/en active Active
- 2020-08-28 CN CN202080074307.XA patent/CN114585606A/zh active Pending
- 2020-08-28 BR BR112022003768A patent/BR112022003768A2/pt not_active IP Right Cessation
- 2020-08-28 MX MX2022002443A patent/MX2022002443A/es unknown
- 2020-08-28 KR KR1020227010196A patent/KR20220068224A/ko not_active Ceased
- 2020-08-28 AU AU2020340427A patent/AU2020340427A1/en not_active Abandoned
-
2022
- 2022-02-24 IL IL290881A patent/IL290881A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7169412B2 (ja) | 抗癌活性及び抗増殖活性を呈する2-アミノピリミジン-6-オン及び類似体 | |
| CN105916845B (zh) | 用于抑制shp2活性的n-氮杂螺环烷取代的n-杂芳基化合物和组合物 | |
| JP6364472B2 (ja) | 抗がんおよび抗増殖活性を示すn−アシル−n’−(ピリジン−2−イル)尿素および類似体 | |
| TWI600654B (zh) | 用於治療寄生蟲疾病之化合物及組合物 | |
| CN105899493A (zh) | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 | |
| RU2007147382A (ru) | Соединения, являющиеся ингибиторами raf, и способы их применения | |
| CN118878461A (zh) | Pd-1/pd-l1抑制剂 | |
| CN115715287A (zh) | 作为IL-12、IL-23和/或IFNα调节剂的经取代的N-(甲基-d3)哒嗪-3-甲酰胺或N-(甲基-d3)-烟酰胺化合物 | |
| TW201524964A (zh) | 治療活性化合物及其使用方法(一) | |
| JP2020526498A5 (cg-RX-API-DMAC7.html) | ||
| CN105473560B (zh) | 治疗活性化合物及其使用方法 | |
| JP2019517487A5 (cg-RX-API-DMAC7.html) | ||
| JP2017505794A5 (cg-RX-API-DMAC7.html) | ||
| JP2017510663A (ja) | Mertk特異的ピリミジン化合物 | |
| JP2008540674A5 (cg-RX-API-DMAC7.html) | ||
| WO2014145029A2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2011520896A5 (cg-RX-API-DMAC7.html) | ||
| JP2014521688A (ja) | インフルエンザウイルス複製の阻害剤 | |
| JP2016539153A (ja) | セリン/トレオニンキナーゼ阻害剤 | |
| KR20240024060A (ko) | 인테그린 억제제에 대한 확장된 투여량 요법 | |
| US9994547B2 (en) | Heteroarylamide inhibitors of TBK1 | |
| RU2015116532A (ru) | Ингибиторы тирозинкиназы syk | |
| JP2025509965A (ja) | がんを治療するための組成物及び方法 | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| JP2022546410A (ja) | Perk阻害化合物 |